Company profile for Regen BioPharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company also developing ...
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6. The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
4700 Spring Street, Suite 304 La Mesa, CA 91942
Telephone
Telephone
(619) 722-5505
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/23/3154642/0/en/Regen-BioPharma-Update-on-Orphan-Drug-Application-for-HemaXellerate-Will-Be-Presented-At-Emerging-Growth-Conference-on-September-24-2025.html

GLOBENEWSWIRE
23 Sep 2025

https://www.globenewswire.com/news-release/2025/09/16/3150748/0/en/Regen-BioPharma-Prepares-Response-For-FDA-Regarding-Its-Orphan-Drug-Application-for-HemaXellerate.html

GLOBENEWSWIRE
16 Sep 2025

https://www.globenewswire.com/news-release/2025/09/04/3144467/0/en/Regen-BioPharma-Explores-Expanded-Use-of-HemaXellerate-for-Chemotherapy-Induced-Bone-Marrow-Suppression.html

GLOBENEWSWIRE
04 Sep 2025

https://www.globenewswire.com/news-release/2025/08/15/3134254/0/en/Regen-BioPharma-Discusses-Potential-Impact-of-HemaXellerate-on-Chemotherapy-Treament-Market.html

GLOBENEWSWIRE
15 Aug 2025

https://www.globenewswire.com/news-release/2025/07/23/3120196/0/en/Regen-BioPharma-Inc-to-Seek-Orphan-Drug-Designation-for-Lead-Product.html

GLOBENEWSWIRE
23 Jul 2025

https://www.globenewswire.com/news-release/2024/11/19/2984018/0/en/Regen-BioPharma-Inc-Expands-Vision-for-Phase-1-Clinical-Trial-of-HemaXellerate.html

GLOBENEWSWIRE
19 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty